Antiplatelet therapy mitigates cardiac remodeling and dysfunction in congestive heart failure due to myocardial...

Area of Science:

• Cardiovascular Pharmacology
• Heart Failure Research
• Myocardial Infarction Therapeutics

Background:

• Peripheral vascular disease is often managed with antiplatelet agents like sarpogrelate (SAR) and cilostazol (CIL).
• Congestive heart failure (CHF) following myocardial infarction (MI) involves cardiac remodeling and impaired function.
• The efficacy of SAR and CIL in mitigating post-MI cardiac remodeling and dysfunction requires further investigation.

Purpose of the Study:

• To test the hypothesis that both SAR and CIL prevent cardiac remodeling and improve cardiac function in rats with MI-induced CHF.
• To compare the effects of SAR and CIL on cardiac function, arrhythmias, and mortality post-MI.

Main Methods:

• Post-MI rats were treated with vehicle, SAR, or CIL for 35 days.
• Sham-operated rats served as controls.
• Electrocardiographic, echocardiographic, and hemodynamic parameters were assessed at day 56.

Main Results:

• Both SAR and CIL significantly improved left ventricular dimensions, systolic and diastolic function, and cardiac output.
• Neither agent affected infarct size or QTc prolongation, though cardiac hypertrophy was reduced.
• SAR decreased ventricular arrhythmias, while CIL increased them; SAR showed a trend towards decreased mortality, whereas CIL trended towards increased mortality.

Conclusions:

• Both sarpogrelate and cilostazol demonstrate cardioprotective effects, preventing cardiac remodeling and improving function in MI-induced CHF.
• Sarpogrelate appears to have a more favorable safety profile regarding arrhythmias and mortality compared to cilostazol in this model.
• These findings suggest differential therapeutic benefits and risks associated with these agents in managing heart failure post-myocardial infarction.